+612 9045 4394
 
CHECKOUT
Handbook of Brain Tumor Chemotherapy - Herbert Newton

Handbook of Brain Tumor Chemotherapy

Hardcover

Published: 13th December 2005
RRP $272.00
$201.25
26%
OFF
or 4 easy payments of $50.31 with Learn more

New Edition View Product

Hardcover
Published: 17th April 2018
$417.75
This title is not in stock at the Booktopia Warehouse and needs to be ordered from our supplier.
Click here to read more about delivery expectations.

Treatment of patients with a brain tumor remains one of the most challenging and difficult areas of modern oncology. Recent advances in the molecular biology of these neoplasms have improved our understanding of the malignant phenotype and have lead to the development of novel forms of chemotherapy, including "targeted" agents. The Handbook of Brain Tumor Chemotherapy reviews the state-of-the-art of chemotherapy development and clinical treatment of patients with this devastating disease.
Handbook of Brain Tumor Chemotherapy offers a unique cutting-edge compendium of basic science and clinical information on the subject of brain tumor chemotherapy, reviewing what has been accomplished thus far and how the field will continue to evolve with the development of more specific and efficacious chemotherapeutic agents. This book represents the most complete single-volume resource available for information on the subject of brain tumor chemotherapy.
* Provides the most up to date information regarding conventional forms of cytotoxic chemotherapy, as well as the basic science and clinical application of molecular therapeutics, for the treatment of brain tumors
* Broadly appeals to anyone interested in the field of Neuro-Oncology and in the treatment of patients with brain tumors
* Useful to clinicians interested in a thorough overview of the use of chemotherapy in patients with a broad range of brain tumors as well as serving as a source of background information to basic scientists and pharmaceutical researchers with an interest in the molecular therapeutics of brain tumors

"4 STARS - Overall, this is an interesting and informative new textbook on brain tumor chemotherapy and molecular therapeutics. It provides a comprehensive, broad overview of the current status of neuro-oncology clinical practice and research." --SURGICAL NEUROLOGY (Vol 66, Issue, 3, September 2006)

"The editor and authors are to be congratulated on providing a timely and valuable reference on chemotherapy for brain tumors. This is a book that will be very useful for all neuro-oncologists and general oncologists treating patients with brain tumors" Patrick Y. Wen, Harvard Medical School, in ONCOLOGY, Vol 20, Number 4, 2006

"In short, the Handbook of Brain Tumor Chemotherapy reflects the hope of recent advances in the treatment of brain tumors and will serve as a solid resource for readers." --Myra R. Rosenfeld, MD, Ph.D., Director, Division of Neuro-oncology, Department of Neurology, University of Pennsylvania, COMMUNITY ONCOLOGY (February 2006)

"In summary, the outstanding style of writing, structure and the multidisciplinary scientific content of this book make this publication a valuable publication. Its price is very reasonable and we highly recommend it to all neuro-oncology clinicians, investigators, and those in training." --Babak Kateb, Behnam Badie, Department of Neurosurgery, City of Hope Medical Center, California, in JOURNAL OF NEUROSURGERY

Contributorsp. xv
Pharmacology and Clinical Applications
Overview of Brain Tumor Epidemiology and Histopathology
Epidemiology of Brain Tumorsp. 3
Pathology of Central Nervous System Tumors-Introductionp. 5
Pathology of Tumors of Neuroepithelial Originp. 6
Pathology of Tumors of the Meningesp. 16
Pathology of Primary CNS Lymphomap. 17
Pathology of Intracranial Germ Cell Tumorsp. 18
Acknowledgmentsp. 19
Clinical Pharmacology of Brain Tumor Chemotherapy
Introductionp. 21
Pharmacology and Drug Distributionp. 21
Supportive Therapeuticsp. 22
Delivery of Chemotherapeutic Agentsp. 24
Chemotherapeutic Agentsp. 25
Alkylating Agentsp. 25
Natural Productsp. 31
Antimetabolitesp. 32
Topoisomerase Inhibitorsp. 34
Miscellaneous Agentsp. 35
Molecular Therapeutic Agentsp. 37
Conclusionsp. 37
Acknowledgmentsp. 38
Chemotherapy and Anti-Epileptic Drug Interactions
Introductionp. 44
Anti-Epileptic Drugs in Neuro-Oncology Patientsp. 44
Drug Metabolism and Resistancep. 45
AED Effects on Hepatic Metabolismp. 46
EIAEDs Effects on Chemotherapyp. 47
Chemotherapy Effects on AEDsp. 49
Practical Effects of AED-Chemotherapy Interactionsp. 49
Practical Managementp. 50
Conclusionsp. 54
Acknowledgmentp. 54
Brain Tumor Models for Cancer Therapy
Rat Brain Tumor Modelsp. 58
Blood-Brain Barrier in Rat Brain Tumor Modelsp. 58
Local Delivery in Rat Brain Tumor Modelsp. 59
Immunological Approaches in Rat Brain Tumor Modelsp. 61
Chemotherapy and Boron Neutron Capture in Rat Brain Tumor Modelsp. 61
Human Brain Tumor Xenograft Modelsp. 62
Blood-Brain Barrier in Human Brain Tumor Xenograft Modelsp. 63
Local Delivery in Human Brain Tumor Xenograft Modelsp. 63
Chemotherapy in Human Brain Tumor Xenograft Modelsp. 64
Angiogenesis in Brain Tumor Modelsp. 65
Conclusionsp. 69
Microarray Analysis and Proteomic Approaches to Drug Development
Introductionp. 74
Microarray Analysisp. 74
Disease Proteomicsp. 76
Implementation of Protein Microarraysp. 77
Gene Expression Patterns in Normal and Diseased Tissuesp. 77
Tumor Expression Profiling: Medulloblastomap. 78
Tumor Expression Profiling: Gliomap. 79
Drug Discoveryp. 81
Gene Expression as a Predictor of Chemosensitivityp. 84
Gene Expression in Response to Drug Therapyp. 84
Summaryp. 84
Chemotherapy Resistance
Common Chemotherapeutic Agents in Gliomasp. 89
DNA Repair and Chemotherapy Resistancep. 90
Detoxification and Other Mechanisms of Resistancep. 95
Summaryp. 98
Clinical Trial Design and Implementation
Introductionp. 105
Phase I Trialsp. 106
Phase II Trialsp. 107
Phase III Clinical Trialsp. 109
Special Challenges of Brain Tumor Trialsp. 109
Conclusionsp. 111
Molecular Biology and Basic Science
Molecular Genetics of Brain Tumors-An Overview
Introductionp. 115
Descriptive Modeling of the Molecular Pathology of Brain Tumorsp. 115
Predictive Modeling of Therapeutic Vulnerability of Brain Tumorsp. 117
Future Directionsp. 120
Regulation of the Cell Cycle and Interventional Developmental Therapeutics
Overviewp. 123
G1 Phasep. 125
S-Phasep. 128
M-Phasep. 129
Therapeutic Small-Molecule Inhibitors of Cell Cyclep. 130
Type I Inhibitors: Direct Inhibitors of CDK Catalytic Activityp. 131
Type II Inhibitors: Inhibitors of CDK Regulatory Mechanismsp. 134
Summaryp. 134
Apoptosis Pathways and Chemotherapy
Architecture of the Major Apoptotic Pathwaysp. 141
Deregulation of Apoptotic Pathways in Brain Tumorsp. 145
Chemotherapeutic Drugs: Mechanism of Action and Impact on Brain Tumorsp. 147
Novel Approaches for the Induction of Apoptosisp. 148
Perspectivep. 151
Growth Factor Signaling Pathways and Receptor Tyrosine Kinase Inhibitors
Introductionp. 155
Glioma Cell Resistance to Conventional Therapeutic Modalitiesp. 155
Platelet-Derived Growth Factor as a Dominant Glioma Mitogenp. 156
EGFR Amplification/Overexpression in Glioma Progressionp. 156
Strategies for Direct Inhibition of Growth Factor Pathway Activationp. 160
STI571 as a Potential PDGFR Inhibitorp. 161
ZD1839 as a Potential EGFR Inhibitorp. 162
Other Small Molecule EGFR Inhibitorsp. 164
Inhibition of Growth Factor Signaling may Interfere with Angiogenesis and Tumor Invasionp. 164
Interference with Growth Factor Receptor Signaling may Potentiate Other Therapiesp. 165
Summaryp. 165
Acknowledgmentp. 166
Ras Signaling Pathways and Farnesyl Transferase Inhibitors
Introductionp. 173
Understanding p21-Ras Structure and Functionp. 174
Role of p21-Ras Mutations in Different Malignanciesp. 178
Farnesyltransferase Inhibitors (FTIs)p. 178
Conclusion and Future Directionsp. 180
PI3-Kinase, PKB/Akt, mTOR, and Internal Signaling Pathways
Overview of the Biology of PI3-kinase and its Effectorsp. 185
Multi-level Dysregulation of PI3-kinase: Implications for Gliomagenesisp. 187
Therapeutic Implicationsp. 188
Tumor Invasiveness and Anti-invasion Strategies
Pathologic Features of Malignant Brain Tumor Invasionp. 193
Clinical and Pathological Evaluation of Tumor Infiltrationp. 193
Patterns of Failurep. 194
Therapeutic Considerationsp. 194
Environmental Influencesp. 195
Molecular Targetsp. 195
Therapeutic Strategiesp. 212
Other Considerationsp. 213
Summaryp. 213
Mechanisms of Angiogenesis in Brain Tumors and their Translation into Therapeutic Anti-tumor Strategies
Summaryp. 219
Introductionp. 219
The Hypoxic Tumor Microenvironment and HIF Activationp. 220
The Hypoxic Tumor Microenvironment, Angiogenesis, and Edemap. 222
The Hypoxic Tumor Microenvironment and Angiogenic Cellular Cross talkp. 224
Anti-angiogenesis Strategies as Novel Anti-tumor Therapiesp. 226
Future Perspectivesp. 230
Acknowledgmentsp. 230
Biology of the Blood-Brain and Blood-Brain Tumor Barriers
The Normal Blood-Brain Barrier: Ultrastructural and Cellular Considerationsp. 236
Functions of the Blood-Brain Barrier; General Factors Affecting Overall Functionp. 238
Drug Movement across the BBB and Determinants of CNS Drug Concentrationp. 239
The "Blood-Brain Tumor" Barrier; Effect of Tumors on the BBBp. 240
Therapeutic Disruption or Circumvention of the BBBp. 241
Conclusionsp. 242
Innovative Approaches to Chemotherapy Delivery
Intra-Arterial Chemotherapy
Introductionp. 247
Pharmacological Rationalep. 247
Single-Agent IA Chemotherapy of Newly Diagnosed Gliomasp. 249
Combination IA Chemotherapy of Newly Diagnosed Gliomasp. 252
Single-Agent IA Chemotherapy of Recurrent Gliomasp. 253
Combination IA Chemotherapy of Recurrent Gliomasp. 255
IA Chemotherapy for Primary CNS Lymphomap. 257
IA Chemotherapy for Brain Metastasesp. 257
Toxicity of IA Chemotherapyp. 257
Conclusionsp. 258
Acknowledgmentsp. 259
Blood-Brain Barrier Disruption Chemotherapy
Introductionp. 262
Pre-clinical BBB Delivery Studiesp. 263
Clinical BBBD Techniquep. 264
Clinical BBBD Resultsp. 267
Pre-clinical Studies of Thiol Chemoprotectionp. 268
Clinical Studies of Thiol Chemoprotectionp. 269
Future BBBD Directionsp. 270
Summaryp. 271
Acknowledgmentsp. 271
Interstitial Chemotherapy and Polymer-Drug Delivery
Introductionp. 274
Physiologic and Pathological Barriers to Anti-Neoplastics in the CNSp. 275
Delivery Systems and Strategies for Brain Tumor Targeted Deliveryp. 276
Development of Polymer-Based Local Delivery Systemsp. 278
BCNU (Gliadel)p. 278
Other Chemotherapeuticsp. 285
Future Directionsp. 288
Conclusionsp. 288
Disclosurep. 290
Intratumoral Administration and Convection-Enhanced Delivery
General Overviewp. 295
Physical Principlesp. 295
Animal Studiesp. 297
Convection-Enhanced Delivery in Animal Brain Tumor Modelsp. 298
Human Studiesp. 299
Challengesp. 302
Marrow Ablative Chemotherapy with Hematopoietic Stem Cell Rescue
Introductionp. 305
Marrow Ablative Therapiesp. 307
Results of High-Dose Chemotherapy and Auto-transplantationp. 309
Conclusionsp. 312
CSF Dissemination of Primary Brain Tumors
Introductionp. 316
General overviewp. 316
Primary brain tumorsp. 318
Treatmentp. 322
Conclusionsp. 326
Chemotherapy-Activating Gene Therapy
Basic Concepts of Gene Therapyp. 332
Activation of Chemotherapy with Gene Therapyp. 332
Clinical Trialsp. 338
Limitations and Problemsp. 340
Conclusionsp. 340
Further Informationp. 340
Chemotherapy of Specific Tumor Types
Chemotherapy of High-Grade Astrocytomas
Introductionp. 347
Overview of Initial Treatmentp. 347
Chemotherapy of AA and GBM-Historical Overviewp. 348
Concomitant Chemotherapy and Irradiation Approachesp. 351
Neoadjuvant Chemotherapy Approachesp. 353
Adjuvant Chemotherapy Approachesp. 355
Chemotherapy for Recurrent High-Grade Astrocytomasp. 356
Conclusionsp. 359
Acknowledgmentsp. 359
Chemotherapy of Low-Grade Astrocytomas
Backgroundp. 364
Pathologic Nomenclaturep. 364
Epidemiologyp. 365
Locationp. 365
Clinical Presentation and Imaging Findingsp. 365
Prognostic Factorsp. 365
Progression and Outcome of LGAp. 366
A Single Randomized Trialp. 366
Phase II Trialsp. 366
Pending Studyp. 369
Chemotherapy of Oligodendrogliomas
Introductionp. 371
Geneticsp. 371
Prognosisp. 372
Anaplastic Oligodendrogliomap. 373
Low-Grade Oligodendrogliomap. 377
Chemotherapy of Oligoastrocytomas
Introductionp. 382
Geneticsp. 383
Prognosisp. 383
Anaplastic Oligoastrocytomasp. 385
Low-Grade Oligoastrocytomasp. 389
Chemotherapy for Primary Central Nervous System Lymphoma
Overviewp. 395
Managementp. 396
Methotrexatep. 396
Intra-arterial MTXp. 397
Maintenance Therapyp. 397
HD-MTX Based Combination Chemotherapy for PCNSLp. 397
Non-Methotrexate Combination Regimensp. 401
Intrathecal Chemotherapyp. 401
Salvage Therapyp. 402
Primary Intraocular Lymphomap. 403
HIV-related PCNSLp. 403
Chemotherapy of Medulloblastoma
Introductionp. 407
Neuro-Imaging and Initial Treatmentp. 408
Chemotherapy of Infants and Very Young Childrenp. 409
Chemotherapy of Children and Adolescentsp. 411
Chemotherapy of Adult Patientsp. 414
Chemotherapy with Bone Marrow Transplantationp. 415
Molecular Genetics and "Targeted" Therapeuticsp. 415
Overview and Future Considerationsp. 419
Acknowledgmentsp. 421
Chemotherapy of Ependymoma
Backgroundp. 426
Trials Dedicated to Ependymomap. 427
Trials Including Ependymomap. 429
Chemotherapy for Glioneuronal Tumors
Introductionp. 432
Central Neurocytomap. 432
Ganglioglioma and Gangliocytomap. 433
Desmoplastic Infantile Ganglioglioma (DIG) and Desmoplastic Infantile Astrocytoma (DIA)p. 434
Dysembryoplastic Neuroepithelial Tumorp. 435
Dysplastic Gangliogliocytoma of the Cerebellump. 435
Cerebellar Liponeurocytomap. 435
Chemotherapy of Pineal Parenchymal Tumors
Pineal Anatomy and Physiologyp. 439
Epidemiologyp. 440
Biology and Molecular Geneticsp. 441
Clinical Presentationp. 442
Neuro-Imaging and Laboratory Diagnosisp. 442
Initial Evaluation and Treatmentp. 443
Chemotherapy of Pineal Parenchymal Tumorsp. 444
Conclusionsp. 445
Acknowledgmentsp. 446
Current Therapeutic Management Strategies for Primary Intracranial Germ Cell Tumors
Introductionp. 448
Epidemiologyp. 449
Clinical Presentationp. 449
Prognostic Variablesp. 450
Therapeutic Effectiveness and Consequent Prognosisp. 451
Long-Term Complications of the Disease and its Therapyp. 458
Conclusionsp. 459
Chemotherapy of Meningiomas
Introduction and Epidemiologyp. 463
Biology and Molecular Geneticsp. 464
Clinical Presentationp. 466
Neuro-Imagingp. 467
Initial Evaluation and Treatmentp. 468
Chemotherapy of Meningiomasp. 469
Conclusionsp. 472
Acknowledgmentsp. 472
Chemotherapy for Brain Metastases
Introductionp. 475
Biology and Molecular Geneticsp. 476
Clinical Presentation and Prognostic Factorsp. 477
Traditional Chemotherapeutic Approachesp. 477
Temozolomidep. 480
Intra-Arterial Treatment Approachesp. 482
Interstitial Chemotherapyp. 483
Molecular Treatment Approachesp. 484
Overview and Future Considerationsp. 485
The Role of Chemotherapy in Pediatric Gliomas
Introductionp. 490
Low-Grade gliomasp. 491
Optic Pathway/Hypothalamic Gliomasp. 493
High-Grade Gliomasp. 494
Diffuse Intrinsic Pontine Gliomasp. 494
High-Dose Chemotherapy and Autologous Stem Cell Rescue in Pediatric Gliomasp. 495
Indexp. 499
Table of Contents provided by Ingram. All Rights Reserved.

ISBN: 9780120884100
ISBN-10: 0120884100
Audience: Professional
Format: Hardcover
Language: English
Number Of Pages: 586
Published: 13th December 2005
Publisher: Elsevier Science Publishing Co Inc
Country of Publication: US
Dimensions (cm): 27.9 x 21.6  x 3.18
Weight (kg): 2.31